Vaccine against Covid-19

Cooperation outside the core areas: Health Developing vaccine production capacity

In order to achieve a more just distribution of COVID-19 vaccines across the globe, Germany supports COVAX, the international vaccine initiative. The German government also provides support for the development of production capacity worldwide, focusing on South Africa, Ghana and Senegal. So far, only a very small proportion of the vaccines used in Africa has been produced locally.

The BMZ is providing a 50 million euro package to support South African partners' efforts to develop local production capacity. Funding is provided for optimising vaccine logistics and cold chain management, and for strengthening regulatory and certification organisations. Training activities and support for research are intended to enable South Africa to also develop other vaccines.

Moreover, the Deutsche Investitions- und Entwicklungsgesellschaft (DEG) has contributed to a financing package for Aspen, a South African company that has produced the Johnson & Johnson vector vaccine under licence since April 2021. This multi-donor funding will enable the company to increase production from 300 million to 600 million doses a year.

As at: 27/12/2022